The DOI matches its Crossref record; 560 of the 560 references it cites were found in a registry or an index.
Antibody Structure and Function: The Basis for Engineering Therapeutics
Open accessAbstract
Antibodies and antibody-derived macromolecules have established themselves as the mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure–function relationships of antibodies provides a platform for protein engineering that has been exploited to generate a wide range of biologics for a host of therapeutic indications. In this review, our basic understanding of the antibody structure is described along with how that knowledge has leveraged the engineering of antibody and antibody-related therapeutics having the appropriate antigen affinity, effector function, and biophysical properties. The platforms examined include the development of antibodies, antibody fragments, bispecific antibody, and antibody fusion products, whose efficacy and manufacturability can be improved via humanization, affinity modulation, and stability enhancement. We also review the design and selection of binding arms, and avidity modulation. Different strategies of preparing bispecific and multispecific molecules for an array of therapeutic applications are included.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 560
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C.-W., Matys, E. R., & Little, M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3156 · Cited by 202
Progress in computational protein design
Lippow, S. M., & Tidor, B. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.04.009 · Cited by 202
Humanization of murine monoclonal antibodies through variable domain resurfacing.
Roguska, M. A., Pedersen, J. T., Keddy, C. A., Henry, A. H., Searle, S. J., Lambert, J. M., Goldmacher, V. S., Blättler, W. A., Rees, A. R., & Guild, B. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.3.969 · Cited by 201
Formation of Pyroglutamic Acid from N-Terminal Glutamic Acid in Immunoglobulin Gamma Antibodies
Chelius, D., Jing, K., Lueras, A., Rehder, D. S., Dillon, T. M., Vizel, A., Rajan, R. S., Li, T., Treuheit, M. J., & Bondarenko, P. V. (2006) · Analytical Chemistry · doi:10.1021/ac051827k · Cited by 200
Johnson, S., Burke, S., Huang, L., Gorlatov, S., Li, H., Wang, W., Zhang, W., Tuaillon, N., Rainey, J., Barat, B., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.04.001 · Cited by 198
Selection of tumor-specific internalizing human antibodies from phage libraries
Poul, M.-A., Becerril, B., Nielsen, U. B., Morisson, P., & Marks, J. D. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4026 · Cited by 192
Design of multivalent complexes using the barnase·barstar module
Deyev, S. M., Waibel, R., Lebedenko, E. N., Schubiger, A. P., & Plückthun, A. (2003) · Nature Biotechnology · doi:10.1038/nbt916 · Cited by 191
Fuh, G., Wu, P., Liang, W.-C., Ultsch, M., Lee, C. V., Moffat, B., & Wiesmann, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507783200 · Cited by 184
Zhou, Q., Shankara, S., Roy, A., Qiu, H., Estes, S., McVie‐Wylie, A., Culm‐Merdek, K., Park, A., Pan, C., & Edmunds, T. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21598 · Cited by 184
Structure-based engineering of a monoclonal antibody for improved solubility
Wu, S.-J., Luo, J., O'Neil, K. T., Kang, J., Lacy, E. R., Canziani, G., Baker, A., Huang, M., Tang, Q. M., Raju, T. S., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq037 · Cited by 183
Self-citationRamaraj, T., Angel, T., Dratz, E. A., Jesaitis, A. J., & Mumey, B. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.12.007 · Cited by 182
The structural repertoire of the human V kappa domain.
Tomlinson, I. M., Cox, J. P., Gherardi, E., Lesk, A. M., & Chothia, C. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00142.x · Cited by 178
Aglycosylated immunoglobulin G1variants productively engage activating Fc receptors
Sazinsky, S. L., Ott, R. G., Silver, N. W., Tidor, B., Ravetch, J. V., & Wittrup, K. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809257105 · Cited by 177
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin
Garcia-Rodriguez, C., Levy, R., Arndt, J. W., Forsyth, C. M., Razai, A., Lou, J., Geren, I., Stevens, R. C., & Marks, J. D. (2007) · Nature Biotechnology · doi:10.1038/nbt1269 · Cited by 177
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Ruf, P., & Lindhofer, H. (2001) · Blood · doi:10.1182/blood.v98.8.2526 · Cited by 174
Mori, K., Kuni‐Kamochi, R., Yamane‐Ohnuki, N., Wakitani, M., Yamano, K., Imai, H., Kanda, Y., Niwa, R., Iida, S., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20326 · Cited by 174
White, A. L., Chan, H. T. C., French, R. R., Willoughby, J., Mockridge, C. I., Roghanian, A., Penfold, C. A., Booth, S. G., Dodhy, A., Polak, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.001 · Cited by 173
PIGS: automatic prediction of antibody structures
Marcatili, P., Rosi, A., & Tramontano, A. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn341 · Cited by 173
Clark, L. A., Boriack‐Sjodin, P. A., Eldredge, J., Fitch, C., Friedman, B., Hanf, K. J. M., Jarpe, M., Liparoto, S. F., Li, Y., Lugovskoy, A., et al. (2006) · Protein Science · doi:10.1110/ps.052030506 · Cited by 173
Alegre, M.-L., Peterson, L. J., Xu, D., Sattar, H. A., Jeyarajah, D. R., Kowalkowski, K., Thistlethwaite, J. R., Zivin, R. A., Jolliffe, L., & Bluestone, J. A. (1994) · Transplantation · doi:10.1097/00007890-199457110-00001 · Cited by 171
Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy
Hu, Y., Liu, C., & Muyldermans, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01442 · Cited by 171
Production of therapeutic antibodies with controlled fucosylation
Yamane-Ohnuki, N., & Satoh, M. (2009) · mAbs · doi:10.4161/mabs.1.3.8328 · Cited by 170
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
Goebeler, M.-E., & Bargou, R. (2016) · Leukemia & Lymphoma · doi:10.3109/10428194.2016.1161185 · Cited by 170
Padlan, E. A. (1991) · Molecular Immunology · doi:10.1016/0161-5890(91)90163-e · Cited by 169
Optimization of Fc-mediated effector functions of monoclonal antibodies
Strohl, W. R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.011 · Cited by 168
Wei, Z., Feng, J., Lin, H.-Y., Mullapudi, S., Bishop, E., Tous, G. I., Casas-Finet, J., Hakki, F., Strouse, R., & Schenerman, M. A. (2007) · Analytical Chemistry · doi:10.1021/ac062311j · Cited by 166
Wang, W., Lu, P., Fang, Y., Hamuro, L., Pittman, T., Carr, B., Hochman, J., & Prueksaritanont, T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039453 · Cited by 166
Taylor, R. P., & Lindorfer, M. A. (2014) · Blood · doi:10.1182/blood-2014-10-569244 · Cited by 163
Klein, J. S., Gnanapragasam, P. N. P., Galimidi, R. P., Foglesong, C. P., West, A. P., & Björkman, P. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811427106 · Cited by 163
The Immunologic Functions of the Neonatal Fc Receptor for IgG
Räth, T., Kuo, T. T., Baker, K., Qiao, S., Kobayashi, K., Yoshida, M., Roopenian, D. C., Fiebiger, E., Lencer, W. I., & Blumberg, R. S. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9768-y · Cited by 162
RosettaAntibody: antibody variable region homology modeling server
Sircar, A., Kim, E. T., & Gray, J. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp387 · Cited by 161
Monoclonal antibody-induced cytokine-release syndrome
Bugelski, P. J., Achuthanandam, R., Capocasale, R. J., Treacy, G., & Bouman-Thio, E. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.31 · Cited by 161
Phage Display Libraries for Antibody Therapeutic Discovery and Development
Almagro, J. C., Pedraza-Escalona, M., Arrieta, H. I., & Pérez-Tapia, S. M. (2019) · Antibodies · doi:10.3390/antib8030044 · Cited by 161
Vafa, O., Gilliland, G. L., Brezski, R. J., Strake, B., Wilkinson, T., Lacy, E. R., Scallon, B. J., Teplyakov, A., Malia, T., & Strohl, W. R. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.035 · Cited by 160
Self-citationBroadly neutralizing antibodies against influenza viruses
Laursen, N. S., & Wilson, I. A. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.03.021 · Cited by 158
Revisiting the Role of Glycosylation in the Structure of Human IgG Fc
Borrok, M. J., Jung, S. T., Kang, T. H., Monzingo, A. F., & Georgiou, G. (2012) · ACS Chemical Biology · doi:10.1021/cb300130k · Cited by 158
Chu, S. Y., Voštiar, I., Karki, S., Moore, G. L., Lazar, G. A., Pong, E., Joyce, P. F., Szymkowski, D. E., & Desjarlais, J. R. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.06.027 · Cited by 157
Structural insights and biomedical potential of IgNAR scaffolds from sharks
Zielonka, S., Empting, M., Grzeschik, J., Könning, D., Barelle, C. J., & Kolmar, H. (2014) · mAbs · doi:10.4161/19420862.2015.989032 · Cited by 155
Lee, C., Romain, G., Yan, W., Watanabe, M., Charab, W., Todorova, B., Lee, J., Triplett, K., Donkor, M. K., Lungu, O. I., et al. (2017) · Nature Immunology · doi:10.1038/ni.3770 · Cited by 155
A novel platform for engineering blood‐brain barrier‐crossing bispecific biologics
Farrington, G. K., Caram‐Salas, N. L., Haqqani, A. S., Brunette, E., Eldredge, J. K., Pepinsky, B., Antognetti, G., Baumann, E., Ding, W., Garber, E. A., et al. (2014) · The FASEB Journal · doi:10.1096/fj.14-253369 · Cited by 154
Engineering therapeutic bispecific antibodies using CrossMab technology
Klein, C., Schäfer, W. M., Regula, J. T., Dumontet, C., Brinkmann, U., Bacac, M., & Umaña, P. (2018) · Methods · doi:10.1016/j.ymeth.2018.11.008 · Cited by 154
Elbow motion in the immunoglobulins involves a molecular ball-and-socket joint
Lesk, A. M., & Chothia, C. (1988) · Nature · doi:10.1038/335188a0 · Cited by 152
Klee, G. G. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0921-hama · Cited by 152
Controlled Fab-arm exchange for the generation of stable bispecific IgG1
Labrijn, A. F., Meesters, J. I., Priem, P., de Jong, R. N., van den Bremer, E. T. J., van Kampen, M. D., Gerritsen, A. F., Schuurman, J., & Parren, P. W. H. I. (2014) · Nature Protocols · doi:10.1038/nprot.2014.169 · Cited by 150
Dheilly, E., Moine, V., Broyer, L., Salgado-Pires, S., Johnson, Z., Papaioannou, A., Cons, L., Calloud, S., Majocchi, S., Nelson, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.006 · Cited by 149
Oliyai, C., & Borchardt, R. T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018981231468 · Cited by 148
Structure-based design of conformation- and sequence-specific antibodies against amyloid β
Perchiacca, J. M., Ladiwala, A. R. A., Bhattacharya, M., & Tessier, P. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111232108 · Cited by 148
Principles of antibody-mediated TNF receptor activation
Wajant, H. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.109 · Cited by 148
Toward Selection of Internalizing Antibodies from Phage Libraries
Becerril, B., Poul, M., & Marks, J. D. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0177 · Cited by 147
Shin, S., Choi, D.-K., Jung, K., Bae, J., Kim, J., Park, S.-W., Song, K.-H., & Kim, Y. (2017) · Nature Communications · doi:10.1038/ncomms15090 · Cited by 146
Second antibody modeling assessment (AMA-II)
Almagro, J. C., Teplyakov, A., Luo, J., Sweet, R. W., Kodangattil, S., Hernandez‐Guzman, F., & Gilliland, G. L. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24567 · Cited by 144
Datta‐Mannan, A., Thangaraju, A., Leung, D., Tang, Y., Witcher, D. R., Lu, J., & Wroblewski, V. J. (2015) · mAbs · doi:10.1080/19420862.2015.1016696 · Cited by 144
Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair
Strop, P., Ho, W.-H., Boustany, L. M., Abdiche, Y. N., Lindquist, K. C., Farias, S., Rickert, M., Appah, C. T., Pascua, E., Radcliffe, T., et al. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.04.020 · Cited by 144
Engineering the variable region of therapeutic IgG antibodies
Igawa, T., Tsunoda, H., Kuramochi, T., Sampei, Z., Ishii, S., & Hattori, K. (2011) · mAbs · doi:10.4161/mabs.3.3.15234 · Cited by 143
Affinity maturation of antibodies assisted by in silico modeling
Barderas, R., Desmet, J., Timmerman, P., Meloen, R. H., & Casal, J. I. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801221105 · Cited by 142
Joachimiak, Ł. A., Kortemme, T., Stoddard, B. L., & Baker, D. A. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.05.022 · Cited by 142
Strohl, W. R., & Naso, M. F. (2019) · Antibodies · doi:10.3390/antib8030041 · Cited by 142
Streltsov, V. A., Varghese, J. N., Carmichael, J. A., Irving, R. A., Hudson, P. J., & Nuttall, S. D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403509101 · Cited by 141
James, L. C., & Tawfik, D. S. (2003) · Protein Science · doi:10.1110/ps.03172703 · Cited by 141
Deamidation and isomerization liability analysis of 131 clinical-stage antibodies
Lu, X., Nobrega, R. P., Lynaugh, H., Jain, T. S., Barlow, K. A., Boland, T., Sivasubramanian, A., Vásquez, M., & Xu, Y. (2018) · mAbs · doi:10.1080/19420862.2018.1548233 · Cited by 141
Wörn, A., der Maur, A. A., Escher, D., Honegger, A., Barberis, A., & Plückthun, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2795 · Cited by 140
Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and tribulations
Sharma, S. K., & Bagshawe, K. D. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.009 · Cited by 137
Datta‐Mannan, A., Witcher, D. R., Tang, Y., Watkins, J. D., Jiang, W., & Wroblewski, V. J. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011734 · Cited by 136
Mimoto, F., Katada, H., Kadono, S., Igawa, T., Kuramochi, T., Muraoka, M., Wada, Y., Haraya, K., Miyazaki, T., & Hattori, K. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt022 · Cited by 136
Jimenez del Val, I., Nagy, J. M., & Kontoravdi, C. (2011) · Biotechnology Progress · doi:10.1002/btpr.688 · Cited by 135
Kunik, V., Ashkenazi, S., & Ofran, Y. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks480 · Cited by 132
Almagro, J. C., Beavers, M. P., Hernandez‐Guzman, F., Maier, J., Shaulsky, J., Butenhof, K., Labute, P., Thorsteinson, N., Kelly, K., Teplyakov, A., et al. (2011) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.23130 · Cited by 131
Self-citationRemmele, R. L., Nightlinger, N. S., Srinivasan, S., & Gombotz, W. R. (1998) · Pharmaceutical Research · doi:10.1023/a:1011902215383 · Cited by 130
Vargas‐Madrazo, E., Lara‐Ochoa, F., & Almagro, J. C. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0633 · Cited by 129
Lloyd, C., Lowe, D., Edwards, B. M., Welsh, F., Dilks, T., Hardman, C. H., & Vaughan, T. J. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn058 · Cited by 128
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0705-5 · Cited by 128
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
Schaer, D., Hirschhorn-Cymerman, D., & Wolchok, J. D. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-7 · Cited by 127
Dick, L. W., Kim, C., Qiu, D., et al. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21260 · Cited by 126
Sankar, K., Krystek, S. R., Carl, S. M., Day, T., & Maier, J. K. X. (2018) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25594 · Cited by 126
ABangle: characterising the VH-VL orientation in antibodies
Dunbar, J., Fuchs, A., Shi, J., & Deane, C. M. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt020 · Cited by 125
Human antibody Fc deamidation in vivo
Liu, D., Enk, J. Z.-V., & Flynn, G. C. (2009) · Biologicals · doi:10.1016/j.biologicals.2009.06.001 · Cited by 124
Improving biophysical properties of a bispecific antibody scaffold to aid developability
von Kreudenstein, T. S., Escobar-Cabrera, E., Lario, P. I., D’Angelo, I., Brault, K., Kelly, J. F., Durocher, Y., Baardsnes, J., Woods, R. J., Xie, M. H., et al. (2013) · mAbs · doi:10.4161/mabs.25632 · Cited by 123
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Furness, A. J. S., Vargas, F. A., Peggs, K. S., & Quezada, S. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.05.002 · Cited by 123
Ryan, M. H., Petrone, D., Nemeth, J. F., Barnathan, E., Björck, L., & Jordan, R. E. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.10.043 · Cited by 122
PyIgClassify: a database of antibody CDR structural classifications
Adolf‐Bryfogle, J., Xu, Q., North, B., Lehmann, A., & Dunbrack, R. L. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku1106 · Cited by 122
Li, B., Tesar, D. B., Boswell, C. A., Cahaya, H. S., Wong, A., Zhang, J., Meng, Y. G., Eigenbrot, C. W., Pantua, H., Diao, J., et al. (2014) · mAbs · doi:10.4161/mabs.29809 · Cited by 121
Tan, G. S., Lee, P. S., Hoffman, R. M. B., Mazel‐Sanchez, B., Krammer, F., Leon, P. E., Ward, A. B., Wilson, I. A., & Palese, P. (2014) · Journal of Virology · doi:10.1128/jvi.02289-14 · Cited by 121
Gautam, R., Nishimura, Y., Gaughan, N. A., Gazumyan, A., Schoofs, T., Buckler-White, A. J., Seaman, M. S., Swihart, B., Follmann, D. A., Nussenzweig, M. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0001-2 · Cited by 121
Construction, expression, and activity of a bivalent bispecific single-chain antibody.
Mallender, W. D., & Voss, E. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42334-9 · Cited by 120
A comparison of biophysical characterization techniques in predicting monoclonal antibody stability
Thiagarajan, G., Semple, A., James, J. K., Cheung, J. K., & Shameem, M. (2016) · mAbs · doi:10.1080/19420862.2016.1189048 · Cited by 120
Stracke, J. O., Emrich, T., Rueger, P., Schlothauer, T., Kling, L., Knaupp, A., Hertenberger, H., Wolfert, A., Spick, C., Lau, W., et al. (2014) · mAbs · doi:10.4161/mabs.29601 · Cited by 119
Domanska, K., Vanderhaegen, S., Srinivasan, V., Pardon, E., Dupeux, F., Márquez, J. A., Giorgetti, S., Stoppini, M., Wyns, L., Bellotti, V., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008560108 · Cited by 119
Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics
Bumbaca, D., Boswell, C. A., Fielder, P. J., & Khawli, L. A. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9369-y · Cited by 119
Kenakin, T., & Morgan, P. H. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10934-6 · Cited by 119
Kim, J., Tsen, M. F., Ghetie, V. F., & Ward, E. S. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240308 · Cited by 118
Structural consensus among antibodies defines the antigen binding site
Kunik, V., Peters, B., & Ofran, Y. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002388 · Cited by 117
Fischer, N., Elson, G., Magistrelli, G., Dheilly, E., Fouque, N., Laurendon, A., Gueneau, F., Ravn, U., Depoisier, J.-F., Moine, V., et al. (2015) · Nature Communications · doi:10.1038/ncomms7113 · Cited by 117
Shibata‐Koyama, M., Iida, S., Okazaki, A., Mori, K., Kitajima-Miyama, K., Saitou, S., Kakita, S., Kanda, Y., Shitara, K., Kato, K., et al. (2008) · Glycobiology · doi:10.1093/glycob/cwn110 · Cited by 117
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
Liu, H., Saxena, A., Sidhu, S. S., & Wu, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00038 · Cited by 117
Human IgG2 Antibody Disulfide Rearrangement in Vivo
Liu, D., Chen, X., Enk, J. Z.-V., Plant, M., Dillon, T. M., & Flynn, G. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804787200 · Cited by 116
Essential role of conformational selection in ligand binding
Vogt, A. D., Pozzi, N., Chen, Z., & Di, E. (2013) · Biophysical Chemistry · doi:10.1016/j.bpc.2013.09.003 · Cited by 116
Engineering Aggregation-Resistant Antibodies
Perchiacca, J. M., & Tessier, P. M. (2012) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-062011-081052 · Cited by 116
Nichols, P., Li, L., Kumar, S., Buck, P. M., Singh, S. K., Goswami, S., Balthazor, B., Conley, T. R., Sek, D., & Allen, M. J. (2015) · mAbs · doi:10.4161/19420862.2014.985504 · Cited by 115
Tanaka, T. U., Lobato, M. N., & Rabbitts, T. H. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00836-2 · Cited by 114
Bernardis, F. D., Liu, H., O’Mahony, R., Valle, R. L., Bartollino, S., Sandini, S., Grant, S., Brewis, N., Tomlinson, I. M., Basset, R. C., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/509891 · Cited by 114
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Trinklein, N. D., Pham, D. T., Schellenberger, U., Buelow, B. D., Boudreau, A. A., Choudhry, P., Clarke, S., Dang, K. H., Harris, K. E., Iyer, S., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1574521 · Cited by 113
Li, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208698109 · Cited by 111
pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling
Borrok, M. J., Wu, Y., Beyaz, N., Yu, X., Oganesyan, V., Dall’Acqua, W. F., & Tsui, P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.603712 · Cited by 111
Rehder, D. S., Chelius, D., McAuley, A., Dillon, T. M., Xiao, G., Crouse-Zeineddini, J., Vardanyan, L., Perico, N., Mukku, V., Brems, D. N., et al. (2008) · Biochemistry · doi:10.1021/bi7018223 · Cited by 110
Almagro, J. C. (2004) · Journal of Molecular Recognition · doi:10.1002/jmr.659 · Cited by 110
The Origin of CDR H3 Structural Diversity
Weitzner, B. D., Dunbrack, R. L., & Gray, J. J. (2015) · Structure · doi:10.1016/j.str.2014.11.010 · Cited by 109
Ni, W., Dai, S., Karger, B. L., & Zhou, Z. S. (2010) · Analytical Chemistry · doi:10.1021/ac101806e · Cited by 109
Perchiacca, J. M., Ladiwala, A. R. A., Bhattacharya, M., & Tessier, P. M. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs042 · Cited by 109
Xu, Y., Szalai, A. J., Zhou, T., Zinn, K. R., Chaudhuri, T. R., Li, X., Koopman, W. J., & Kimberly, R. P. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.562 · Cited by 108
A molecular immunology approach to antibody humanization and functional optimization
Lazar, G. A., Desjarlais, J. R., Jacinto, J. M., Karki, S., & Hammond, P. W. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.09.029 · Cited by 107
Pairing of variable heavy and variable kappa chains in individual naive and memory B cells.
Brezinschek, H. P., Foster, S. J., Dörner, T., Brezinschek, R. I., & Lipsky, P. E. (1998) · PubMed · Cited by 106
Modeling the anti‐CEA antibody combining site by homology and conformational search
Mas, M. T., Smith, K. C., Yarmush, D. L., Aisaka, K., & Fine, R. (1992) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.340140409 · Cited by 105
He, L.-Z., Prostak, N., Thomas, L. J., Vitale, L. A., Weidlick, J., Crocker, A., Pilsmaker, C. D., Round, S. M., Tutt, A., Glennie, M. J., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300409 · Cited by 104
Warncke, M., Calzascia, T., Coulot, M., Balke, N., Touil, R., Kolbinger, F., & Heusser, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200090 · Cited by 104
Tan, P., Mitchell, D. A., Buss, T. N., Holmes, M. A., Anasetti, C., & Foote, J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.2.1119 · Cited by 102
Edwards, B. M., Barash, S. C., Main, S. H., Choi, G. H., Minter, R., Ullrich, S. J., Williams, E. M., Fou, L. D., Wilton, J., Albert, V. R., et al. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.09.054 · Cited by 102
Mangsbo, S. M., Broos, S., Fletcher, E. A. K., Veitonmäki, N., Furebring, C., Dahlén, E., Norlén, P., Lindstedt, M., Tötterman, T. H., & Ellmark, P. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0913 · Cited by 102
Roux, K. H., Strelets, L., Brekke, O. H., Sandlie, I., & Michaelsen, T. E. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4083 · Cited by 102
How to Distinguish Conformational Selection and Induced Fit Based on Chemical Relaxation Rates
Paul, F., & Weikl, T. R. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005067 · Cited by 101
Thermostability of Biological Systems: Fundamentals, Challenges, and Quantification
He, X. (2011) · The Open Biomedical Engineering Journal · doi:10.2174/1874120701105010047 · Cited by 100
Lebozec, K., Jandrot‐Perrus, M., Avenard, G., Favre‐Bulle, O., & Billiald, P. (2017) · mAbs · doi:10.1080/19420862.2017.1336592 · Cited by 100
Analyzing the ‘Degree of Humanness’ of antibody sequences
Abhinandan, K. R., & Martin, A. C. R. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.100 · Cited by 99
DiJoseph, J. F., Goad, M. E. P., Dougher, M. M., Boghaert, E. R., Kunz, A., Hamann, P. R., & Damle, N. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1134 · Cited by 99
Assessment of disulfide and hinge modifications in monoclonal antibodies
Moritz, B., & Stracke, J. O. (2016) · Electrophoresis · doi:10.1002/elps.201600425 · Cited by 99
Use of human germline genes in a CDR homology-based approach to antibody humanization
Hwang, W. Y. K., Almagro, J. C., Buss, T. N., Tan, P., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.004 · Cited by 97
Hutmacher, C., & Neri, D. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.002 · Cited by 97
Kiyoshi, M., Caaveiro, J. M. M., Miura, E., Nagatoishi, S., Nakakido, M., Soga, S., Shirai, H., Kawabata, S., & Tsumoto, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087099 · Cited by 96
Klarenbeek, A., Mazouari, K. E., Desmyter, A., Blanchetot, C., Hultberg, A., Jonge, N. D., Roovers, R. C., Cambillau, C., Spinelli, S., Del‐Favero, J., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1046648 · Cited by 96
PADLAN, E. A. (1977) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583500000135 · Cited by 96
Antibody glycoengineering strategies in mammalian cells
Wang, Q., Chung, C., Chough, S., & Betenbaugh, M. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26567 · Cited by 95 · cited 1×
“The specific glycan attachments (fucosylation, sialylation, galactosylation, highmannose, and bisecting glycans) have great importance to the antibody properties [213,214] (See Figure 5).”
BackgroundMonoclonal antibody humanness score and its applications
Gao, S. H., Huang, K., Tu, H., & Adler, A. S. (2013) · BMC Biotechnology · doi:10.1186/1472-6750-13-55 · Cited by 95
Weitzner, B. D., Kuroda, D., Marze, N. A., Xu, J., & Gray, J. J. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24534 · Cited by 95
Wu, C., Hua, Y., Bose, S., Miller, R., Medina, L., Santora, L. C., & Ghayur, T. (2009) · mAbs · doi:10.4161/mabs.1.4.8755 · Cited by 94
Li, Y., Polozova, A., Gruia, F., & Feng, J. (2014) · Analytical Chemistry · doi:10.1021/ac404218t · Cited by 93
Kovalenko, O. V., Olland, A. M., Piche‐Nicholas, N., Godbole, A., King, D., Svenson, K., Calabro, V., Müller, M. R., Barelle, C. J., Somers, W. S., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.435289 · Cited by 93
Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies
Roopenian, D. C., Christianson, G. J., & Sproule, T. J. (2006) · Methods in molecular biology · doi:10.1007/978-1-60761-058-8_6 · Cited by 92
Huber, A. H., Kelley, R. F., Gastinel, L. N., & Björkman, P. J. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1220 · Cited by 92
Ha, J.-H., Kim, J.-E., & Kim, Y. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00394 · Cited by 92
Maier, J. K. X., & Labute, P. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24576 · Cited by 91
Cochlovius, B., Kipriyanov, S. M., Stassar, M. J. J. G., Schuhmacher, J., Benner, A., Moldenhauer, G., & Little, M. (2000) · PubMed · Cited by 91
Pelat, T., Bedouelle, H., Rees, A. R., Crennell, S. J., Lefranc, M., & Thullier, P. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.033 · Cited by 91
Pairing of Variable Heavy and Variable κ Chains in Individual Naive and Memory B Cells
Brezinschek, H. P., Foster, S. J., Dörner, T., Brezinschek, R. I., & Lipsky, P. E. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.10.4762 · Cited by 91
Datta‐Mannan, A., Lu, J., Witcher, D. R., Leung, D., Tang, Y., & Wroblewski, V. J. (2015) · mAbs · doi:10.1080/19420862.2015.1075109 · Cited by 90
When binding is enough: nonactivating antibody formats
Labrijn, A. F., Aalberse, R. C., & Schuurman, J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.010 · Cited by 90
Analysis and prediction of VH/VL packing in antibodies
Abhinandan, K. R., & Martin, A. C. R. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq043 · Cited by 90
Raghunathan, G., Smart, J., Williams, J. F., & Almagro, J. C. (2012) · Journal of Molecular Recognition · doi:10.1002/jmr.2158 · Cited by 88
Kovaleva, M., Ferguson, L., Steven, J., Porter, A. J., & Barelle, C. J. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.937701 · Cited by 87
Remodeling domain interfaces to enhance heterodimer formation
Zhu, Z., Presta, L. G., Zapata, G. A., & Carter, P. M. (1997) · Protein Science · doi:10.1002/pro.5560060404 · Cited by 87
Antibody humanization by structure-based computational protein design
Choi, Y., Hua, C. K., Sentman, C. L., Ackerman, M. E., & Bailey‐Kellogg, C. (2015) · mAbs · doi:10.1080/19420862.2015.1076600 · Cited by 86
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
Zhukovsky, E. A., Morse, R. J., & Maus, M. V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.006 · Cited by 86
Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.
Riethmüller, G. (2012) · Europe PMC (PubMed Central) · Cited by 85
Lack of specificity of antibodies directed against human beta-adrenergic receptors
Hamdani, N., & van der Velden, J. (2009) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-009-0392-1 · Cited by 84
Cole, M. S., Stellrecht, K. E., Shi, J. D., et al. (1999) · Transplantation · doi:10.1097/00007890-199908270-00020 · Cited by 84
The formation of a specific inhibitor by hydrolysis of rabbit antiovalbumin
Porter, R. R. (1950) · Biochemical Journal · doi:10.1042/bj0460479 · Cited by 84
Controlling glycation of recombinant antibody in fed‐batch cell cultures
Yuk, I. H. Y., Zhang, B., Yang, Y., Dutina, G., Leach, K., Vijayasankaran, N., Shen, A. Y., Andersen, D. C., Snedecor, B. R., & Joly, J. C. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23218 · Cited by 83
Somatic insertions and deletions shape the human antibody repertoire 1 1Edited by J. Karn
de Wildt, R. M. T., VENROOIJ, W. J. V., Winter, G. P., Hoet, R. M. A., & Tomlinson, I. M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3289 · Cited by 82
Immunoglobulin G1 Fc Domain Motions: Implications for Fc Engineering
Frank, M., Walker, R. C., Lanzilotta, W. N., Prestegard, J. H., & Barb, A. W. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.01.011 · Cited by 82
Feng, M., Bian, H.-J., Wu, X., Fu, T., Fu, Y., Hong, J., Fleming, B. D., Flajnik, M. F., & Ho, M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby011 · Cited by 82
He, F., Woods, C. E., Trilisky, E. I., Bower, K. M., Litowski, J. R., Kerwin, B. A., Becker, G. W., Narhi, L. O., & Razinkov, V. I. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22384 · Cited by 81
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
Dubuisson, A., & Micheau, O. (2017) · Antibodies · doi:10.3390/antib6040016 · Cited by 81
A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
Yeung, Y. A., Wu, X., Reyes, A. E., Vernes, J.-M., Lien, S., Lowe, J. A., III, Maia, M., Forrest, W. F., Meng, Y. G., Damico, L. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4580 · Cited by 80
Treatment of Human B Cell Lymphoma Xenografts with a CD3 × CD19 Diabody and T Cells
Cochlovius, B., Kipriyanov, S. M., Stassar, M. J. J. G., Christ, O., Schuhmacher, J., Strauß, G., Moldenhauer, G., & Little, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.2.888 · Cited by 80
Shechter, Y. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42431-8 · Cited by 79
Epithelial Junction Opener JO-1 Improves Monoclonal Antibody Therapy of Cancer
Beyer, I., van Rensburg, R., Strauss, R., Li, Z., Wang, H., Persson, J., Yumul, R., Feng, Q., Song, H., Bártek, J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2009 · Cited by 79
Antigen binding allosterically promotes Fc receptor recognition
Zhao, J., Nussinov, R., & Ma, B. (2018) · mAbs · doi:10.1080/19420862.2018.1522178 · Cited by 79
Liu, Z., Leng, E. C., Gunasekaran, K., Pentony, M., Shen, M., Howard, M., Stoops, J. D., Manchulenko, K., Razinkov, V. I., Liu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620260 · Cited by 78
Ott, M., Marmé, F., Moldenhauer, G., Lindhofer, H., Hennig, M., Spannagl, R., Essing, M. M., Linke, R., & Seimetz, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.26258 · Cited by 77
Engineering and Pharmacology of Blood–Brain Barrier-Permeable Bispecific Antibodies
Stanimirovic, D. B., Kemmerich, K., Haqqani, A. S., & Farrington, G. K. (2014) · Advances in pharmacology · doi:10.1016/bs.apha.2014.06.005 · Cited by 77
Liu, L., Stadheim, A., Hamuro, L., Pittman, T. J., Wang, W., Zha, D., Hochman, J. H., & Prueksaritanont, T. (2011) · Biologicals · doi:10.1016/j.biologicals.2011.06.002 · Cited by 76
Liu, Z., Gunasekaran, K., Wang, W., Razinkov, V. I., Sekirov, L., Leng, E. C., Sweet, H., Foltz, I. N., Howard, M., Rousseau, A.-M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.513366 · Cited by 76
Dillon, M., Yin, Y., Zhou, J., McCarty, L., Ellerman, D., Slaga, D., Junttila, T. T., Han, G., Sandoval, W., Ovacik, M. A., et al. (2017) · mAbs · doi:10.1080/19420862.2016.1267089 · Cited by 75
Delivery of antibodies to the cytosol: Debunking the myths
Marschall, A. L. J., Zhang, C., Frenzel, A., Schirrmann, T., Hust, M., Perez, F., & Dübel, S. (2014) · mAbs · doi:10.4161/mabs.29268 · Cited by 75
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies
Yang, F., Wen, W., & Qin, W. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010048 · Cited by 75
Graziano, R. F., Tempest, P. R., White, P., Keler, T., Deo, Y. M., Ghebremariam, H., Coleman, K. D., Pfefferkorn, L. C., Fanger, M. W., & Guyre, P. M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.10.4996 · Cited by 74
Aggregation of recombinant human growth hormone induced by phenolic compounds
Maa, Y., & Hsu, C. C. (1996) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(96)04577-2 · Cited by 74
Moore, G. L., Bernett, M. J., Rashid, R., Pong, E., Nguyen, D.-H. T., Jacinto, J. M., Eivazi, A., Nisthal, A., Diaz, J. E., Chu, S. Y., et al. (2018) · Methods · doi:10.1016/j.ymeth.2018.10.006 · Cited by 74
Pedotti, M., Simonelli, L., Livoti, E., & Varani, L. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12010226 · Cited by 73
Choi, D.-K., Bae, J., Shin, S.-M., Shin, J.-Y., Kim, Y., & Kim, Y. (2014) · mAbs · doi:10.4161/mabs.36389 · Cited by 73
Mimoto, F., Igawa, T., Kuramochi, T., Katada, H., Kadono, S., Kamikawa, T., Shida-Kawazoe, M., & Hattori, K. (2013) · mAbs · doi:10.4161/mabs.23452 · Cited by 73
IgG2 Fc structure and the dynamic features of the IgG CH2–CH3 interface
Teplyakov, A., Zhao, Y., Malia, T., Obmolova, G., & Gilliland, G. L. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.03.018 · Cited by 73
Self-citationOrtiz, D. F., Lansing, J. C., Rutitzky, L. I., Kurtagic, E., Prod’homme, T., Choudhury, A., Washburn, N., Bhatnagar, N., Beneduce, C., Holte, K., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9418 · Cited by 73
Antibody modeling assessment II. Structures and models
Teplyakov, A., Luo, J., Obmolova, G., Malia, T. J., Sweet, R., Stanfield, R. L., Kodangattil, S., Almagro, J. C., & Gilliland, G. L. (2014) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24554 · Cited by 72
Self-citationA Focused Antibody Library for Improved Hapten Recognition
Persson, H., Lantto, J., & Ohlin, M. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.01.004 · Cited by 72
Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule
Jakob, C. G., Edalji, R. P., Judge, R. A., DiGiammarino, E. L., Li, Y., Gu, J., & Ghayur, T. (2013) · mAbs · doi:10.4161/mabs.23977 · Cited by 72
Influence of glycosylation pattern on the molecular properties of monoclonal antibodies
Zheng, K., Yarmarkovich, M., Bantog, C., Bayer, R. J., & Patapoff, T. W. (2014) · mAbs · doi:10.4161/mabs.28588 · Cited by 71
Goodchild, S. A., Dooley, H. M., Schoepp, R. J., Flajnik, M. F., & Lonsdale, S. G. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.06.437 · Cited by 69
Tietze, L. F., Major, F., & Schuberth, I. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600936 · Cited by 69
Germline VH/VL pairing in antibodies
Jayaram, N., Bhowmick, P., & Martin, A. C. R. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs043 · Cited by 69
Lam, X. M., Lai, W. G., Chan, E. K., et al. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0482-x · Cited by 68
Shin, T. H., Sung, E.-S., Kim, Y., Kim, S.-H., Kim, S.-K., Kim, S.-K., Lee, Y., & Kim, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0748 · Cited by 68
Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
Zhang, D., Goldberg, M. V., & Chiu, M. L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.757773 · Cited by 68
Self-citationIndustrial bioprocessing perspectives on managing therapeutic protein charge variant profiles
Chung, S., Tian, J., Tan, Z., Chen, J., Lee, J., Borys, M., & Li, Z. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26587 · Cited by 68
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells
Lee, C. V., Hymowitz, S. G., Wallweber, H. J. A., et al. (2006) · Blood · doi:10.1182/blood-2006-03-011031 · Cited by 67
The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases
Cardinale, A., & Biocca, S. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.07.004 · Cited by 67
Roguska, M., Pedersen, J. T., Henry, A. H., Searle, S. M. J., Roja, C. M., Avery, B. J., Hoffee, M., Cook, S., Lambert, J. M., Blättler, W. A., et al. (1996) · Protein Engineering Design and Selection · doi:10.1093/protein/9.10.895 · Cited by 67
Schoonjans, R., Willems, A. V., Schoonooghe, S., Fiers, W. C., Grooten, J., & Mertens, N. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7050 · Cited by 67
van den Bremer, E. T. J., Beurskens, F. J. M., Voorhorst, M., Engelberts, P. J., de Jong, R. N., van der Boom, B. G., Cook, E. M., Lindorfer, M. A., Taylor, R. P., van Berkel, P. H. C., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1046665 · Cited by 66
Béhar, G., Chames, P., Navarro‐Teulon, I., Cornillon, A., Al-Shoukr, F., Roquet, F., Pugnière, M., Teillaud, J., Gruaz‐Guyon, A., Pèlegrin, A., et al. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07101.x · Cited by 66
Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody
Walsh, R., Nuttall, S. D., Revill, P. A., Colledge, D., Cabuang, L. M., Soppe, S., Dolezal, O., Griffiths, K., Bartholomeusz, A., & LOCARNINI, S. A. (2011) · Virology · doi:10.1016/j.virol.2010.12.034 · Cited by 66
Cited by
Olsen, T. H., Boyles, F., & Deane, C. M. (2022) · Protein Science · doi:10.1002/pro.4205 · Cited by 319
ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins
Abanades, B., Wong, W. K., Boyles, F., Georges, G., Bujotzek, A., & Deane, C. M. (2023) · Communications Biology · doi:10.1038/s42003-023-04927-7 · Cited by 298
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
AFsample: improving multimer prediction with AlphaFold using massive sampling
Wallner, B. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad573 · Cited by 164
ABlooper: fast accurate antibody CDR loop structure prediction with accuracy estimation
Abanades, B., Georges, G., Bujotzek, A., & Deane, C. M. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac016 · Cited by 157
Metadata
- Authors
- Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2019-12-03
- Volume
- 8
- Issue
- 4
- Pages
- 55
- ISSN
- 2073-4468 (ISSN-L)
- OpenAlex
- W2993866869
- Cited by
- 638
- References
- 560
- FWCI
- 28.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.